Clinical Trial Update: Pharmacokinetic and Safety Study of MRX-2843 in Adolescents and Adults With Relapsed/Refractory AML, ALL, or MPAL [Phase 1]

View source ↗

Summary

Phase 1 pharmacokinetic and safety study of MRX-2843 in adolescents and adults with relapsed/refractory acute myeloid leukemia, acute lymphoblastic leukemia, or…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Acute Myeloid Leukemia
• Mixed Phenotype Acute Leukemia

Drugs mentioned

• MRX-2843 (mrx-2843)

Snippet

Sponsor: Meryx, Inc. | Conditions: Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia | Phase 1 | Status: RECRUITING